Sinphar Pharmaceutical Co.,Ltd. (TPE:1734)

Market Cap	6.11B +5.2%
Revenue (ttm)	3.37B +7.0%
Net Income	365.75M +20.0%
EPS	1.92 +20.0%
Shares Out	190.20M
PE Ratio	16.74
Forward PE	n/a
Dividend	1.00 (3.11%)
Ex-Dividend Date	Jul 11, 2025

Volume	507,365
Average Volume	343,260
Open	32.05
Previous Close	32.10
Day's Range	31.90 - 32.25
52-Week Range	29.05 - 32.60
Beta	0.13
RSI	65.64
Earnings Date	May 13, 2026

About Sinphar Pharmaceutical

Sinphar Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the production, processing, selling, and trading of various medicines, chinese medicines, medical cosmetic products and nutrients in Taiwan, Mainland China, Vietnam, Indonesia, and internationally. It operates through three segments: Pharmaceuticals, Healthy Food, and Others. The company offers pharmaceutical products, including antineoplastic, ophthalmic, ENT, oral, respiratory system, dermatology, analgesic and NSAIDs, metabolic and nutrient, gastrointestinal, and oth...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1977
• Country: Taiwan
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 1734

Financial Performance

In 2025, Sinphar Pharmaceutical's revenue was 3.37 billion, an increase of 7.00% compared to the previous year's 3.15 billion. Earnings were 365.75 million, an increase of 20.03%.